Mettlach Sarah E, Zealand Cameron M, Botero Tatiana M, Boynton James R, Majewski Robert F, Hu Jan ChingChun
Department of Cariology, Restorative Sciences, and Endodontics, University of Michigan, Ann Arbor, Mich., USA.
Pediatr Dent. 2013 May-Jun;35(3):E87-94.
The purpose of this study was to test the hypothesis that there is no significant difference in the clinical and radiographic outcomes of diluted formocresol (DFC) compared to gray mineral trioxide aggregate (GMTA) pulpotomy in human primary molars.
A total of 152 children with 252 primary molars met selection criteria. Of those, 119 and 133 teeth were randomly assigned to the GMTA and DFC groups, respectively. Periapical radiographs, taken pre- and/or postoperatively and at each 6-month follow-up, were digitized and evaluated by three blinded and calibrated examiners.
Over a 42-month period, a total of 865 clinical and radiographic evaluations were conducted. There was no significant difference in clinical success, with the cumulative proportion of GMTA-treated teeth surviving at 0.98 vs DFC-treated teeth at 0.95 (P>.05). Radiographic success, however, was significantly greater for GMTA vs DFC, with the cumulative proportion of GMTA-treated teeth surviving at 0.90 vs DFC-treated teeth at 0.47 (P<.001). Overall, DFC-treated teeth were 5.1 times more likely to fail than GMTA-treated teeth. Radiographic pathologies were observed more frequently in the DFC-treated teeth (P<.05).
Gray mineral trioxide aggregate can be considered an acceptable replacement for diluted formocresol when used as a medicament for primary molar pulpotomies.
本研究的目的是检验以下假设:在人类乳磨牙中,稀释甲酚醛(DFC)与灰色矿物三氧化物凝聚体(GMTA)活髓切断术的临床和影像学结果无显著差异。
共有152名患有252颗乳磨牙的儿童符合入选标准。其中,119颗和133颗牙齿分别被随机分配到GMTA组和DFC组。术前和/或术后以及每6个月随访时拍摄的根尖片被数字化,并由三名不知情且经过校准的检查人员进行评估。
在42个月的时间里,共进行了865次临床和影像学评估。临床成功率无显著差异,GMTA治疗的牙齿存活的累积比例为0.98,而DFC治疗的牙齿为0.95(P>0.05)。然而,GMTA的影像学成功率显著高于DFC,GMTA治疗的牙齿存活的累积比例为0.90,而DFC治疗的牙齿为0.47(P<0.001)。总体而言,DFC治疗的牙齿失败的可能性是GMTA治疗的牙齿的5.1倍。在DFC治疗的牙齿中更频繁地观察到影像学病变(P<0.05)。
当用作乳磨牙活髓切断术的药物时,灰色矿物三氧化物凝聚体可被视为稀释甲酚醛的可接受替代品。